蛋白酶抑制剂市场－全球产业规模、份额、趋势、机会和预测，依疾病适应症、最终用途、地区和竞争格局划分，2020-2030年预测

2024年全球蛋白酶抑制剂市场规模为69.2亿美元，预计2030年将以4.76%的复合年增长率成长至91.5亿美元。蛋白酶抑制剂是一类旨在阻断蛋白酶活性的治疗药物。蛋白酶是切割某些关键蛋白质所必需的酶，这些蛋白质对于特定病毒的复製和某些疾病的进展至关重要。全球蛋白酶抑制剂市场的成长主要得益于病毒感染（包括爱滋病和C型肝炎）的日益流行，以及生物技术的不断进步，这些进步带来了更多标靶性化合物。

主要市场驱动因素

慢性病和传染病的日益普及是全球蛋白酶抑制剂市场需求的主要驱动因素。全球疾病负担的不断加重，尤其是人类免疫缺陷病毒（HIV）感染，迫切需要持续研发并扩大有效治疗手段的可近性。

主要市场挑战

药物抗药性的持续出现严重阻碍了全球蛋白酶抑制剂市场的扩张。这项挑战直接降低了现有治疗药物的疗效，因为标靶病毒和致病因子会发展出规避药物作用的机制。

主要市场趋势

治疗应用的多元化是全球蛋白酶抑制剂市场的一大关键趋势，使其应用范围超越了现有的抗病毒适应症。蛋白酶抑制剂过去主要用于治疗爱滋病和丙型肝炎等疾病，如今正被探索和开发用于治疗更广泛的疾病，包括各种癌症、发炎性疾病和神经系统疾病。

目录

第一章：产品概述

第二章：研究方法

第三章：执行概要

第四章：顾客之声

第五章：全球蛋白酶抑制剂市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依疾病指征（HIV/AIDS、C型肝炎、α1-抗胰蛋白酶缺乏症、遗传性血管性水肿（HAE）、其他）
  • 依最终用途（医院和诊所、研究实验室和学术机构、其他）
  • 按地区
  • 按公司（2024 年）
• 市场地图

第六章：北美蛋白酶抑制剂市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲蛋白酶抑制剂市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区蛋白酶抑制剂市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲蛋白酶抑制剂市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿联酋
  • 南非

第十章：南美洲蛋白酶抑制剂市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章：市场动态

• 司机
• 挑战

第十二章：市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章：全球蛋白酶抑制剂市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商议价能力
• 顾客的力量
• 替代产品的威胁

第十五章：竞争格局

• Boehringer Ingelheim International GmbH
• Cytoskeleton, Inc.
• Genentech, Inc.
• Merck & Co., Inc.
• Thermo Fisher Scientific, Inc.
• Kerry Group plc
• Mycorena AB
• Omega Protein Corporation

第十六章：策略建议

第17章调查会社について・免责事项

The Global Protease Inhibitors Market, valued at USD 6.92 Billion in 2024, is projected to experience a CAGR of 4.76% to reach USD 9.15 Billion by 2030. Protease inhibitors constitute a class of therapeutic agents designed to obstruct the activity of proteases, enzymes essential for the cleavage of proteins critical to the replication of specific viruses and the progression of certain diseases. The global market for these inhibitors is largely supported by the increasing prevalence of viral infections, including HIV/AIDS and hepatitis C, coupled with ongoing advancements in biotechnology that yield more targeted compounds.

Key Market Drivers

The increasing prevalence of chronic and infectious diseases serves as a fundamental demand-side driver for the global protease inhibitors market. The escalating global burden of conditions, particularly human immunodeficiency virus HIV infection, necessitates continuous development and broader access to effective therapeutic interventions. Protease inhibitors remain crucial in HIV management.

Key Market Challenges

The persistent emergence of drug resistance represents a considerable impediment to the expansion of the Global Protease Inhibitors Market. This challenge directly diminishes the efficacy of current therapeutic agents, as target viruses and disease-causing agents develop mechanisms to circumvent drug action. Such evolution reduces the effective lifespan of existing protease inhibitor treatments and continuously drives the need for costly and prolonged research into novel compounds with new mechanisms of action.

Key Market Trends

The diversification of therapeutic applications represents a pivotal trend for the Global Protease Inhibitors Market, expanding its reach beyond established antiviral indications. Historically central to managing conditions like HIV and Hepatitis C, protease inhibitors are increasingly being explored and developed for a broader spectrum of diseases, including various forms of cancer, inflammatory disorders, and neurological conditions. This strategic broadening of focus is driven by a deeper mechanistic understanding of protease involvement in diverse pathological processes, leading to the identification of novel targets suitable for inhibition.

Key Market Players

• Boehringer Ingelheim International GmbH
• Cytoskeleton, Inc.
• Genentech, Inc.
• Merck & Co., Inc.
• Thermo Fisher Scientific, Inc.
• Kerry Group plc
• Mycorena AB
• Omega Protein Corporation

Report Scope:

In this report, the Global Protease Inhibitors Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Protease Inhibitors Market, By Disease indication:

• HIV/AIDS
• Hepatitis C
• Alpha-1 Antitrypsin Deficiency
• Hereditary Angioedema (HAE)
• Others

Protease Inhibitors Market, By End-Use:

• Hospitals & Clinics
• Research Laboratories and Academic Institutes
• Others

Protease Inhibitors Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Protease Inhibitors Market.

Available Customizations:

Global Protease Inhibitors Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Protease Inhibitors Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Disease indication (HIV/AIDS, Hepatitis C, Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema (HAE), Others)
  • 5.2.2. By End-Use (Hospitals & Clinics, Research Laboratories and Academic Institutes, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Protease Inhibitors Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Disease indication
  • 6.2.2. By End-Use
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Protease Inhibitors Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Disease indication
      • 6.3.1.2.2. By End-Use
  • 6.3.2. Canada Protease Inhibitors Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Disease indication
      • 6.3.2.2.2. By End-Use
  • 6.3.3. Mexico Protease Inhibitors Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Disease indication
      • 6.3.3.2.2. By End-Use

7. Europe Protease Inhibitors Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Disease indication
  • 7.2.2. By End-Use
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Protease Inhibitors Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Disease indication
      • 7.3.1.2.2. By End-Use
  • 7.3.2. France Protease Inhibitors Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Disease indication
      • 7.3.2.2.2. By End-Use
  • 7.3.3. United Kingdom Protease Inhibitors Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Disease indication
      • 7.3.3.2.2. By End-Use
  • 7.3.4. Italy Protease Inhibitors Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Disease indication
      • 7.3.4.2.2. By End-Use
  • 7.3.5. Spain Protease Inhibitors Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Disease indication
      • 7.3.5.2.2. By End-Use

8. Asia Pacific Protease Inhibitors Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Disease indication
  • 8.2.2. By End-Use
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Protease Inhibitors Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Disease indication
      • 8.3.1.2.2. By End-Use
  • 8.3.2. India Protease Inhibitors Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Disease indication
      • 8.3.2.2.2. By End-Use
  • 8.3.3. Japan Protease Inhibitors Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Disease indication
      • 8.3.3.2.2. By End-Use
  • 8.3.4. South Korea Protease Inhibitors Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Disease indication
      • 8.3.4.2.2. By End-Use
  • 8.3.5. Australia Protease Inhibitors Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Disease indication
      • 8.3.5.2.2. By End-Use

9. Middle East & Africa Protease Inhibitors Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Disease indication
  • 9.2.2. By End-Use
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Protease Inhibitors Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Disease indication
      • 9.3.1.2.2. By End-Use
  • 9.3.2. UAE Protease Inhibitors Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Disease indication
      • 9.3.2.2.2. By End-Use
  • 9.3.3. South Africa Protease Inhibitors Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Disease indication
      • 9.3.3.2.2. By End-Use

10. South America Protease Inhibitors Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Disease indication
  • 10.2.2. By End-Use
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Protease Inhibitors Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Disease indication
      • 10.3.1.2.2. By End-Use
  • 10.3.2. Colombia Protease Inhibitors Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Disease indication
      • 10.3.2.2.2. By End-Use
  • 10.3.3. Argentina Protease Inhibitors Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Disease indication
      • 10.3.3.2.2. By End-Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Protease Inhibitors Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Boehringer Ingelheim International GmbH
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Cytoskeleton, Inc.
• 15.3. Genentech, Inc.
• 15.4. Merck & Co., Inc.
• 15.5. Thermo Fisher Scientific, Inc.
• 15.6. Kerry Group plc
• 15.7. Mycorena AB
• 15.8. Omega Protein Corporation

16. Strategic Recommendations

17. About Us & Disclaimer